Home » Market News » DirectorsTalk Highlights » Open Orphan wins £2.5 million contract for Influenza human challenge study
Open Orphan PLC

Open Orphan wins £2.5 million contract for Influenza human challenge study

Open Orphan plc (LON:ORPH), a rapidly growing specialist CRO pharmaceutical services company which is the world leader in the testing of vaccines and antivirals using human challenge clinical trials, has announced the signing of a £2.5 million contract by hVIVO, a subsidiary of Open Orphan, to conduct an Influenza human challenge study with a US biotechnology company.

The study is expected to commence at hVIVO’s 24-bedroom quarantine clinic in East London in H2 2021 and to be fully completed by year end 2021, generating £2.5m of revenue. This contract builds on the Company’s recent challenge study contract wins in RSV and COVID-19 and demonstrates the breadth of Open Orphan’s service offering and the expertise within the Group as a world leader in its field.

For this study, Venn Life Science’s Paris team will complete the biometrics, demonstrating how the various parts of the Open Orphan plc Group can work together to deliver high-quality services to clients. Venn’s Paris team are highly regarded in the field as one of the leading providers in this area which is a perfect complement to the London offering.

Cathal Friel, Executive Chairman, Open Orphan, said:

“We are delighted to be conducting this influenza challenge study, recent events have highlighted the importance of treatments for viral infections such as influenza and we are seeing an increased level of interest amongst both pharma and biotech in developing innovative new vaccines, antivirals, and therapeutics.

The Company is pleased to be continuing to deliver on our pipeline of opportunities. This has been due to the exceptional work from the hVIVO team, building on the Company’s long history as the world leading challenge study provider. Both the team and I are excited to see the progress being made by the Group and look forward to continuing the momentum as we rapidly grow the business to maximise shareholder value.”